Announcements Trials

Browse Landscape

Phase

Status

Terminated 14 Completed 9 Recruiting 4 Withdrawn 1 Unknown 1 Suspended 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 6 Leukemia, Myeloid, Acute 3 Carcinoma, Renal Cell 3 Ovarian Cancer Metastatic 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Lymphoma, B-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Kidney Neoplasms 1 Invasive Bladder Cancer Stage IV 1 Hormone Refractory Prostate Cancer 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Brain Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

Radiosurgery 7 Oxaliplatin 7 Docetaxel 7 Paclitaxel 5 Fluorouracil 5 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Gemcitabine 4 Carboplatin 4 Capecitabine 4 Trastuzumab 3 Radiotherapy 3 Radiation 3 Leucovorin 3 Erlotinib Hydrochloride 3 Cyclophosphamide 3 Cetuximab 3 Bevacizumab 3 spartalizumab 2 sipuleucel-T 2 repotrectinib 2 pembrolizumab 2 pazopanib 2 orteronel 2 fludarabine 2 atezolizumab 2 aldesleukin 2 Temozolomide 2 Surveys and Questionnaires 2 Sunitinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasm Metastasis × Interleukin-2 × Clear all

NCT03226236 2018-11-13

RENALVax-2

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Withdrawn

Carcinoma, Renal Cell, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡